BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, we were able to observe various behavior of the Ph+ iPSCs obtained from the same CML patients, in terms of BCR-ABL1 pattern, sensitivity to imatinib and hematopoietic differentiation.